{
  "id": "63eeec79f36125a426000006",
  "type": "factoid",
  "question": "Talquetamab was developed for treatment of which disease?",
  "ideal_answer": "Talquetamab was developed for treatment of multiple myeloma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36352205",
    "http://www.ncbi.nlm.nih.gov/pubmed/36006441"
  ],
  "snippets": [
    {
      "text": "Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The bispecific antibodies teclistamab (BCMA\u00d7CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "multiple myeloma"
}